Dow Showdown: Pfizer vs. Alcoa

Before you go, we thought you'd like these...
Before you go close icon

This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and industrials editor/analyst Isaac Pino discuss topics across the investing world.

Continuing our Motley Fool Madness series, Isaac and David go head-to-head analyzing Pfizer and Alcoa. In this showdown, Alcoa enters as the No. 12 seed, as the company's stock outperformed the majority of its Dow peers over the past three years. Despite Pfizer's troubles with the patent cliff, the big pharma heavyweight is still a formidable opponent with an attractive dividend.

While Isaac and David present strong arguments for both companies, a team of all-star Motley Fool analysts will ultimately select who advances in the Dow bracket.

Investors looking for solid American stocks that are expanding their global footprint should look no further than The Motley Fool's recent special free report, "3 Companies Set to Dominate the World." The report is free today but won't be forever, so check out your copy today by clicking here. Enjoy, and Fool on!

At the time this article was published David Williamson owns shares of Pfizer. Isaac Pino has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above.Motley Fool newsletter services recommendPfizer and Tesla Motors. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners